Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation
administered to HIV infected or exposed children and infants (0 to 13 years of age). An
evaluation of the relative bioavailability of the pediatric powder formulation vs. a standard
tablet formulation in older children (7 to 13 years of age) will also be conducted.